Loading...
•
Sep 30, 2021
CareDx Q3 2021 Earnings Report
Achieved record revenue driven by testing services volume growth.
Key Takeaways
CareDx reported a strong third quarter with record revenue of $75.6 million, a 42% increase year-over-year. Testing services volume grew 86% year-over-year. The company increased its full-year revenue guidance to $290 million to $293 million.
Achieved record revenue of $75.6 million, a 42% increase year-over-year.
Testing services volume grew 86% year-over-year, with approximately 40,000 AlloSure and AlloMap patient results.
Announced publication of KidneyCare validation study in Kidney360.
Received first commercial AlloSure Lung coverage and launched AlloSure Lung commercially.
Revenue by Segment
Forward Guidance
CareDx now expects revenue to be in the range of $290 million to $293 million for the full year 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...